Szczeklik A, Pietoń R, Sieradzki J
J Allergy Clin Immunol. 1980 Nov;66(5):424-7. doi: 10.1016/0091-6749(80)90123-2.
In 31 patients with atopic bronchial asthma in clinical remission and in 21 healthy sex- and age-matched subjects, the responses to intravenous tolbutamide (1.0 gm) and insulin (0.1 U/kg) were studied over a period of 2 hr. In response to tolbutamide, asthmatics released significantly less insulin, but their blood glucose levels did not differ from those of controls. Asthmatics also reacted to tolbutamide-induced hypoglycemia with significantly greater output of growth hormone to blood. Following intravenous injection of insulin, the recovery of the blood glucose concentrations was significantly reduced in asthmatic patients. More economical use of insulin and increased responsiveness to its hypoglycemic action, together with the well-known reduction in hypoglycemic effects of catecholamines in bronchial asthma, might explain why asthmatics rarely develop diabetes mellitus.
对31例处于临床缓解期的特应性支气管哮喘患者以及21名年龄和性别匹配的健康受试者,在2小时内研究了他们对静脉注射甲苯磺丁脲(1.0克)和胰岛素(0.1单位/千克)的反应。对甲苯磺丁脲的反应中,哮喘患者释放的胰岛素明显较少,但他们的血糖水平与对照组无差异。哮喘患者对甲苯磺丁脲诱导的低血糖反应时,血液中生长激素的分泌量也显著增加。静脉注射胰岛素后,哮喘患者血糖浓度的恢复明显减慢。胰岛素使用更经济且对其降糖作用的反应性增加,再加上支气管哮喘中儿茶酚胺的降糖作用明显降低,可能解释了为什么哮喘患者很少发生糖尿病。